Merck & Co, Inc provides healthcare solutions worldwide. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory diseases.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Phone908-740-4000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$42.29 billion
Profitability
Miscellaneous
Employees69,000
Next Earnings Date10/29/2019 (Confirmed)
OptionableOptionable
Merck & Co., Inc. (NYSE:MRK) Frequently Asked Questions
What is Merck & Co., Inc.'s stock symbol?
Merck & Co., Inc. trades on the New York Stock Exchange (NYSE) under the ticker symbol "MRK."
How often does Merck & Co., Inc. pay dividends? What is the dividend yield for Merck & Co., Inc.?
Merck & Co., Inc. declared a quarterly dividend on Tuesday, July 23rd. Investors of record on Monday, September 16th will be paid a dividend of $0.55 per share on Monday, October 7th. This represents a $2.20 dividend on an annualized basis and a dividend yield of 2.60%. The ex-dividend date of this dividend is Friday, September 13th. View Merck & Co., Inc.'s Dividend History.
How will Merck & Co., Inc.'s stock buyback program work?
Merck & Co., Inc. declared that its Board of Directors has approved a share buyback plan on Thursday, October 25th 2018, which allows the company to buyback $10,000,000,000.00 in shares, according to EventVestor. This buyback authorization allows the company to reacquire up to 5.1% of its shares through open market purchases. Shares buyback plans are typically a sign that the company's board believes its shares are undervalued.
How were Merck & Co., Inc.'s earnings last quarter?
Merck & Co., Inc. (NYSE:MRK) issued its earnings results on Tuesday, July, 30th. The company reported $1.30 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $1.16 by $0.14. The business had revenue of $11.76 billion for the quarter, compared to analyst estimates of $10.94 billion. Merck & Co., Inc. had a return on equity of 43.34% and a net margin of 21.10%. The business's revenue for the quarter was up 12.4% on a year-over-year basis. During the same period in the previous year, the company posted $1.06 EPS. View Merck & Co., Inc.'s Earnings History.
When is Merck & Co., Inc.'s next earnings date?
How can I listen to Merck & Co., Inc.'s earnings call?
Merck & Co., Inc. will be holding an earnings conference call on Tuesday, October 29th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.
What guidance has Merck & Co., Inc. issued on next quarter's earnings?
Merck & Co., Inc. issued an update on its FY19 earnings guidance on Tuesday, July, 30th. The company provided earnings per share (EPS) guidance of $4.84-4.94 for the period, compared to the Thomson Reuters consensus estimate of $4.82. The company issued revenue guidance of $45.2-46.2 billion, compared to the consensus revenue estimate of $44.68 billion.
What price target have analysts set for MRK?
17 analysts have issued 12 month price objectives for Merck & Co., Inc.'s shares. Their forecasts range from $80.00 to $105.00. On average, they anticipate Merck & Co., Inc.'s stock price to reach $94.07 in the next twelve months. This suggests a possible upside of 11.1% from the stock's current price. View Analyst Price Targets for Merck & Co., Inc..
What is the consensus analysts' recommendation for Merck & Co., Inc.?
17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Merck & Co., Inc. in the last year. There are currently 3 hold ratings and 14 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Merck & Co., Inc..
What are Wall Street analysts saying about Merck & Co., Inc. stock?
Here are some recent quotes from research analysts about Merck & Co., Inc. stock:
- 1. Mizuho analysts commented, "We like shares of MRK driven by KEYTRUDA’s penetration of global markets in multiple indications, which we believe will drive P&L transformation. While KEYTRUDA is growing in dominance, both in the market and on MRK’s P&L, we see MRK as having considerable runway (2028 LOE) to address concerns regarding concentration of revenue." (9/8/2019)
- 2. According to Zacks Investment Research, "Merck’s new products like Keytruda, Lynparza, and Bridion are contributing meaningfully to the top line. Keytruda sales are gaining momentum with approval for additional indications, especially in the first-line lung cancer setting. Keytruda has strong growth prospects based on increased utilization, recent approvals for new indications and potential additional approvals worldwide. Animal health and vaccine products are also performing strongly and remain core growth drivers for Merck. The company will continue to focus on cost-cutting initiatives to drive the bottom line. However, generic competition for several drugs and pricing pressure will continue to be overhangs on the top line. Rising competitive pressure on the diabetes franchise and products like Isentress (HIV), Zepatier (HCV) and Zostavax (vaccine) remains a concern. Merck’s shares have outperformed the industry this year. " (4/1/2019)
- 3. Cantor Fitzgerald analysts commented, "We rate MRK 12-month PT of $95. We think there is upside to Keytruda sales estimates. Sales growth across oncology, vaccines, animal health, and select hospital/specialty care products, as well as margin-expansion opportunities, are underappreciated, in our view. Therefore, we expect upward earnings revisions and multiple expansion in 2019+ to drive MRK’s shares higher. Valuation Summary We arrive at our 12-month price target of $95 for Merck shares by using a blend of Base case analyses." (3/29/2019)
Has Merck & Co., Inc. been receiving favorable news coverage?
Media stories about MRK stock have trended somewhat negative this week, InfoTrie Sentiment reports. The research group ranks the sentiment of media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Merck & Co., Inc. earned a daily sentiment score of -1.5 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the next few days. View News Stories for Merck & Co., Inc..
Are investors shorting Merck & Co., Inc.?
Merck & Co., Inc. saw a increase in short interest in the month of September. As of September 30th, there was short interest totalling 21,470,000 shares, an increase of 19.4% from the August 30th total of 17,980,000 shares. Based on an average trading volume of 8,810,000 shares, the days-to-cover ratio is currently 2.4 days. Approximately 0.8% of the shares of the company are short sold. View Merck & Co., Inc.'s Current Options Chain.
Who are some of Merck & Co., Inc.'s key competitors?
Some companies that are related to Merck & Co., Inc. include Johnson & Johnson (JNJ), Roche Holdings AG Basel (RHHBY), Pfizer (PFE), Novartis (NVS), Abbott Laboratories (ABT), Novo Nordisk A/S (NVO), AstraZeneca (AZN), Sanofi (SNY), AbbVie (ABBV), GlaxoSmithKline (GSK), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), Commonwealth Bank of Australia (CSLLY), Celgene (CELG) and Bayer (BAYRY).
What other stocks do shareholders of Merck & Co., Inc. own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Merck & Co., Inc. investors own include Pfizer (PFE), AT&T (T), Johnson & Johnson (JNJ), Intel (INTC), Cisco Systems (CSCO), Verizon Communications (VZ), Walt Disney (DIS), JPMorgan Chase & Co. (JPM), Exxon Mobil (XOM) and General Electric (GE).
Who are Merck & Co., Inc.'s key executives?
Merck & Co., Inc.'s management team includes the folowing people:
- Mr. Kenneth C. Frazier, Chairman, Pres & CEO (Age 64)
- Mr. Robert M. Davis, Exec. VP of Global Services & CFO (Age 52)
- Ms. Jennifer L. Zachary, Exec. VP & Gen. Counsel (Age 41)
- Dr. Roger M. Perlmutter, Exec. VP & Pres of Merck Research Laboratories (Age 67)
- Mr. Adam H. Schechter, Special Advisor (Age 54)
Who are Merck & Co., Inc.'s major shareholders?
Merck & Co., Inc.'s stock is owned by many different of institutional and retail investors. Top institutional investors include Robeco Institutional Asset Management B.V. (0.15%), CIBC Private Wealth Group LLC (0.09%), Envestnet Asset Management Inc. (0.05%), Zurcher Kantonalbank Zurich Cantonalbank (0.05%), Gateway Investment Advisers LLC (0.05%) and Manning & Napier Group LLC (0.04%). Company insiders that own Merck & Co., Inc. stock include Adam H Schechter, Ashley Watson, Frank Clyburn, Julie L Gerberding, Kenneth C Frazier, Leslie A Brun, Merck & Co, Inc, Michael J Holston, Richard R Deluca, Rita A Karachun, Robert M Davis, Roger M Perlmutter, Sanat Chattopadhyay, Thomas H Glocer, Weir Mirian M Graddick and Wendell P Weeks. View Institutional Ownership Trends for Merck & Co., Inc..
Which major investors are selling Merck & Co., Inc. stock?
MRK stock was sold by a variety of institutional investors in the last quarter, including Manning & Napier Group LLC, Varma Mutual Pension Insurance Co, Chesley Taft & Associates LLC, DNB Asset Management AS, Gateway Investment Advisers LLC, Robeco Institutional Asset Management B.V., Hexavest Inc. and Country Club Trust Company n.a.. Company insiders that have sold Merck & Co., Inc. company stock in the last year include Adam H Schechter, Ashley Watson, Frank Clyburn, Julie L Gerberding, Kenneth C Frazier, Leslie A Brun, Richard R Deluca, Rita A Karachun, Robert M Davis, Roger M Perlmutter, Sanat Chattopadhyay, Thomas H Glocer and Wendell P Weeks. View Insider Buying and Selling for Merck & Co., Inc..
Which major investors are buying Merck & Co., Inc. stock?
MRK stock was purchased by a variety of institutional investors in the last quarter, including Rhenman & Partners Asset Management AB, Atalanta Sosnoff Capital LLC, Gradient Investments LLC, Reilly Financial Advisors LLC, State of Alaska Department of Revenue, Envestnet Asset Management Inc., Bowling Portfolio Management LLC and Assenagon Asset Management S.A.. View Insider Buying and Selling for Merck & Co., Inc..
How do I buy shares of Merck & Co., Inc.?
Shares of MRK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Merck & Co., Inc.'s stock price today?
One share of MRK stock can currently be purchased for approximately $84.68.
How big of a company is Merck & Co., Inc.?
Merck & Co., Inc. has a market capitalization of $216.81 billion and generates $42.29 billion in revenue each year. The company earns $6.22 billion in net income (profit) each year or $4.34 on an earnings per share basis. Merck & Co., Inc. employs 69,000 workers across the globe.View Additional Information About Merck & Co., Inc..
What is Merck & Co., Inc.'s official website?
How can I contact Merck & Co., Inc.?
Merck & Co., Inc.'s mailing address is 2000 GALLOPING HILL ROAD, KENILWORTH NJ, 07033. The company can be reached via phone at 908-740-4000 or via email at [email protected]
MarketBeat Community Rating for Merck & Co., Inc. (NYSE MRK)
MarketBeat's community ratings are surveys of what our community members think about Merck & Co., Inc. and other stocks. Vote "Outperform" if you believe MRK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MRK will underperform the S&P 500 over the long term. You may vote once every thirty days.
